Rocephin and Ifosfamide drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Rocephin (ceftriaxone sodium) and Ifosfamide (ifosfamide). Common drug interactions include encephalopathy among females and febrile bone marrow aplasia among males.

The phase IV clinical study analyzes what interactions people have when they take Rocephin and Ifosfamide. It is created by eHealthMe based on reports of 12 people who take the same drugs from the FDA, and is updated regularly.

What is Rocephin?

Rocephin has active ingredients of ceftriaxone sodium. It is often used in infection. eHealthMe is studying from 15,665 Rocephin users. Check the latest studies of Rocephin.

What is Ifosfamide?

Ifosfamide has active ingredients of ifosfamide. eHealthMe is studying from 21,285 Ifosfamide users. Check the latest studies of Ifosfamide.



On Jul, 26, 2026

12 people who take Rocephin and Ifosfamide together, and have interactions are studied.

Rocephin and Ifosfamide drug interactions.

What are the common drug interactions of Rocephin and Ifosfamide, by gender? *:

female:

  1. Encephalopathy (functioning of the brain is affected by some agent or condition)
  2. Malignant neoplasm progression (cancer tumour came back)
  3. Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection)
  4. Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets)
  5. Thrombosis (formation of a blood clot inside a blood vessel)
  6. Multi-organ failure (multisystem organ failure)

male:

  1. Febrile bone marrow aplasia (bone marrow greatly decreases or stops production of blood cells)
  2. Mucosal inflammation (infection of mucous membrane)
  3. Headache (pain in head)
  4. Insomnia (sleeplessness)
  5. Lung infection
  6. Lymphoma (cancer that begins in immune system cells)
  7. Mouth ulceration (mouth ulcers)
  8. Nasopharyngitis (inflammation of the nasopharynx)
  9. Neuropathy peripheral (surface nerve damage)
  10. Pericardial effusion (fluid around the heart)

What are the common drug interactions of Rocephin and Ifosfamide, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

  1. Febrile bone marrow aplasia (bone marrow greatly decreases or stops production of blood cells)
  2. Mucosal inflammation (infection of mucous membrane)

10-19:

  1. Bone marrow failure
  2. Cardiac arrest
  3. Decreased appetite
  4. Lung infection
  5. Lymphoma (cancer that begins in immune system cells)
  6. Mouth ulceration (mouth ulcers)
  7. Respiratory arrest (cessation of normal respiration due to failure of the lungs to function effectively)
  8. Urinary bladder haemorrhage (urinary bladder bleeding)

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

  1. Decreased appetite
  2. Dizziness
  3. Headache (pain in head)
  4. Insomnia (sleeplessness)
  5. Multi-organ failure (multisystem organ failure)
  6. Nasopharyngitis (inflammation of the nasopharynx)
  7. Neuropathy peripheral (surface nerve damage)
  8. Pneumonia pseudomonal (pseudomonas pneumonia is an infection caused by the microbe known as pseudomonas aeruginosa)
  9. Pyrexia (fever)
  10. Rhinorrhoea (watery mucus discharge from the nose)

60+:

  1. Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection)
  2. Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets)
  3. Thrombosis (formation of a blood clot inside a blood vessel)
  4. Pericardial effusion (fluid around the heart)
  5. Pleural effusion (water on the lungs)
  6. Pyrexia (fever)

What are the existing conditions these people have? *

  1. Rhabdomyosarcoma (cancer of the bone, soft tissues, or connective tissue (e.g., tendon or cartilage)): 5 people, 41.67%
  2. Non-Hodgkin's Lymphoma (malignant (cancer) cells form in the lymph system): 4 people, 33.33%
  3. Lymphoma (cancer that begins in immune system cells): 1 person, 8.33%
  4. Lung Infection: 1 person, 8.33%
  5. Burkitt's Lymphoma (cancer of the lymphatic system): 1 person, 8.33%
  6. Burkitt Lymphoma (cancer of the lymphatic system): 1 person, 8.33%

* Approximation only. Some reports may have incomplete information.

Do you take Rocephin and Ifosfamide?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Rocephin and Ifosfamide:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Rocephin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Ifosfamide:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Rocephin and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Ifosfamide and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies


How the study uses the data?

The study uses data from the FDA. It is based on ceftriaxone sodium and ifosfamide (the active ingredients of Rocephin and Ifosfamide, respectively), and Rocephin and Ifosfamide (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: